Clinical trial · Interventional
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
NCT06895928CI-TRIAL-00088795recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adebelimab Injection | Drug | — | UNRESOLVED |
| Ametinib Mesylate Tablets | Drug | — | UNRESOLVED |
| Bevacizumab Injection | Drug | Bevacizumab | ALIAS |
| Osimertinib Mesylate Tablets | Drug | Osimertinib | ALIAS |
| SHR-A2102 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment Group
- interventionNames
- Drug: SHR-A2102
- Drug: Bevacizumab Injection
- Drug: Adebelimab Injection
- Drug: Ametinib Mesylate Tablets
- Drug: Osimertinib Mesylate Tablets
Primary outcomes (3)
- measure
- Adverse events (AEs)
- timeFrame
- From day 1 to 90 days after the last dose.
- measure
- Serious adverse events (SAEs)
- timeFrame
- From day 1 to 90 days after the last dose.
- measure
- Objective response rate (ORR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. The age of signing the informed consent is 18 -70 years, regardless of gender. 2. At least one measurable lesion according to RECIST v1.1 criteria. 3. The ECOG score is 0 or 1. 4. Expected survival ≥12 weeks. 5. Good level of organ function. 6. Have the ability to give informed consent and to comply with the treatment plan. 7. Male subjects whose partners are women of childbearing age and female subjects who are fertile are required to use highly effective contraceptive methods. Exclusion Criteria: 1. Inadequately treated central nervous system metastases or the presence of uncontrolled or symptomatic active central nervous system metastases. 2. Spinal cord compression not cured by surgery and/or radiotherapy. 3. Subjects with uncontrolled tumor-related pain. 4. Received antitumor therapy within 4 weeks before the start of the study. 5. Subjects with severe cardiovascular and cerebrovascular disease. 6. History of immunodeficiency, including a positive HIV test.
References
Publications (0)
Data not yet available
No reference posted for this study.